ACORDA THERAPEUTICS INC (ACOR)
US00484M7002 - Common Stock
We assign a fundamental rating of 0 out of 10 to ACOR. ACOR was compared to 588 industry peers in the Biotechnology industry. ACOR may be in some trouble as it scores bad on both profitability and health. ACOR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ACOR had negative earnings in the past year.
In the past year ACOR has reported a negative cash flow from operations.
In the past 5 years ACOR always reported negative net income.
ACOR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ACOR (-233.00%) is worse than 90.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-90.83%
ROA(5y)-64.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ACOR (86.92%) is better than 90.61% of its industry peers.
ACOR's Gross Margin has improved in the last couple of years.
ACOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y1.97%
2. Health
2.1 Basic Checks
ACOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACOR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACOR has more shares outstanding
ACOR has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -16.36, we must say that ACOR is in the distress zone and has some risk of bankruptcy.
ACOR has a worse Altman-Z score (-16.36) than 83.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.36 |
ROIC/WACCN/A
WACC5.57%
2.3 Liquidity
A Current Ratio of 0.33 indicates that ACOR may have some problems paying its short term obligations.
The Current ratio of ACOR (0.33) is worse than 96.42% of its industry peers.
ACOR has a Quick Ratio of 0.33. This is a bad value and indicates that ACOR is not financially healthy enough and could expect problems in meeting its short term obligations.
ACOR's Quick ratio of 0.26 is on the low side compared to the rest of the industry. ACOR is outperformed by 97.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.33 | ||
| Quick Ratio | 0.26 |
3. Growth
3.1 Past
The earnings per share for ACOR have decreased strongly by -129.75% in the last year.
Looking at the last year, ACOR shows a decrease in Revenue. The Revenue has decreased by -0.77% in the last year.
ACOR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.24% yearly.
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1202.02%
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y-24.24%
Revenue growth Q2Q20.59%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACOR. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ACOR indicates a rather cheap valuation: ACOR is cheaper than 97.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.69 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ACOR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACORDA THERAPEUTICS INC
NASDAQ:ACOR (4/11/2024, 7:00:01 PM)
After market: 0.5656 -0.1 (-14.43%)0.661
-0.22 (-24.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap821.03K
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.33 | ||
| Quick Ratio | 0.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y